(NASDAQ: LEXX) Lexaria Bioscience's forecast annual revenue growth rate of -10.05% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 104.73%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.61%.
Lexaria Bioscience's revenue in 2025 is $615,923.On average, 5 Wall Street analysts forecast LEXX's revenue for 2026 to be $15,651,059, with the lowest LEXX revenue forecast at $7,667,198, and the highest LEXX revenue forecast at $23,999,113. On average, 4 Wall Street analysts forecast LEXX's revenue for 2027 to be $27,989,185, with the lowest LEXX revenue forecast at $26,893,871, and the highest LEXX revenue forecast at $28,810,671.
In 2028, LEXX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.